Fundsmith Investment Services LTD. Acquires 20,163 Shares of Stryker Co. (NYSE:SYK)

Fundsmith Investment Services LTD. grew its holdings in Stryker Co. (NYSE:SYK) by 1.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,908,979 shares of the medical technology company’s stock after buying an additional 20,163 shares during the quarter. Stryker makes up 8.9% of Fundsmith Investment Services LTD.’s portfolio, making the stock its 3rd largest position. Fundsmith Investment Services LTD. owned 0.50% of Stryker worth $687,328,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Kohmann Bosshard Financial Services LLC bought a new stake in Stryker during the 4th quarter worth about $25,000. Rakuten Securities Inc. lifted its holdings in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after buying an additional 68 shares during the period. Centricity Wealth Management LLC acquired a new stake in Stryker during the 4th quarter worth $30,000. BankPlus Trust Department bought a new stake in shares of Stryker during the 4th quarter valued at $33,000. Finally, Activest Wealth Management acquired a new stake in shares of Stryker during the fourth quarter worth $36,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

SYK opened at $383.84 on Thursday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The business has a 50 day moving average of $365.90 and a 200-day moving average of $374.10. The stock has a market cap of $146.51 billion, a price-to-earnings ratio of 49.46, a PEG ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.50 EPS. On average, equities research analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SYK. Needham & Company LLC reissued a “buy” rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. JPMorgan Chase & Co. increased their price target on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Truist Financial lifted their price objective on Stryker from $390.00 to $400.00 and gave the company a “hold” rating in a report on Monday. Royal Bank of Canada boosted their price objective on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Finally, Stifel Nicolaus raised their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $427.05.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.